OnCo
trialsTrialActive

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

A phase 2 trial of Siltuximab in Multiple myeloma, run by Memorial Sloan Kettering Cancer Center, active and no longer recruiting.